Beyond Air, Inc. (XAIR) Stock Analysis and Metrics

Sector: Healthcare Industry: Medical Devices CIK: 0001641631

Market Cap 2.21 Mn

P/E 0.08

P/S 0.32

Div. Yield 0.00

Total Debt (Qtr) 21.97 Mn

Revenue Growth (1y) (Qtr) 104.66

Add ratio to table...

About

Beyond Air, Inc., with its ticker symbol XAIR, is a commercial-stage medical device and biopharmaceutical company that operates in the healthcare industry. The company's main business activities involve the development and commercialization of medical devices and biopharmaceuticals that utilize nitric oxide (NO) to treat various respiratory and pulmonary diseases. Beyond Air generates revenue through the sale of its primary products, including LungFit PH, LungFit PRO, and LungFit GO. These products are designed to deliver NO to patients with various...

Beyond Air, Inc., with its ticker symbol XAIR, is a commercial-stage medical device and biopharmaceutical company that operates in the healthcare industry. The company's main business activities involve the development and commercialization of medical devices and biopharmaceuticals that utilize nitric oxide (NO) to treat various respiratory and pulmonary diseases.

Beyond Air generates revenue through the sale of its primary products, including LungFit PH, LungFit PRO, and LungFit GO. These products are designed to deliver NO to patients with various respiratory and pulmonary diseases, including persistent pulmonary hypertension of the newborn (PPHN), viral community-acquired pneumonia (VCAP), bronchiolitis, and non-tuberculous mycobacteria (NTM) lung infection.

LungFit PH is the company's first FDA-approved system that generates on-demand NO from ambient air. The device uses a medical air compressor to drive room air through a plasma chamber, where pulses of electrical discharge are created between two electrodes. The system uses the power equivalent to a 60-watt lightbulb to ionize the nitrogen and oxygen molecules, which then combine as NO with low levels of nitrogen dioxide (NO2) created as a byproduct. The system then passes the products through a Smart Filter, which removes the toxic NO2 from the internal circuit. LungFit PH is designed to deliver a dosage of NO to the lungs that is consistent with current guidelines for delivery of 20 ppm NO with a range of 0.5 ppm to 80 ppm (low concentration NO) for ventilated patients.

LungFit PRO is designed to treat patients with VCAP and bronchiolitis. The device uses a proprietary delivery system to deliver high concentrations of NO to the lungs, which has been shown to be effective in shortening hospital length of stay and accelerating time to fit for discharge. LungFit GO is designed to treat patients with NTM lung infection. The device uses a proprietary delivery system to deliver high concentrations of NO to the lungs, which has been shown to be effective in reducing microbial load and improving quality of life.

Beyond Air believes that its competitive advantages include its ability to generate NO from ambient air, which eliminates the need for high-pressure cylinders and cumbersome purging procedures. The company's devices also have a lower burden on hospital staff, as they do not require the same level of safety procedures as traditional NO delivery systems.

The company's customers include hospitals and healthcare providers that treat patients with respiratory and pulmonary diseases. The company's products are designed to be used in a variety of settings, including hospitals, clinics, and home care settings.

Beyond Air has a strong intellectual property portfolio, with over 50 pending patent applications worldwide. The company has also entered into a settlement agreement with Circassia Limited and its affiliates, resolving all claims by and between both parties and mutually terminating the agreement.

The company is subject to government regulation in the United States, with the FDA regulating drug and medical device products under the Federal Food, Drug, and Cosmetic Act. The company's products have been designated as devices by the FDA and will be regulated by the Center for Devices and Radiological Health. The company is required to obtain 510(k) clearance or PMA approval from the FDA before commercially distributing its products.

In terms of brand names and/or trade names, Beyond Air has LungFit PH, LungFit PRO, and LungFit GO as its primary products in development and commercialization. These products have the potential to generate significant revenue in the future, with financial projections including U.S. sales potential for LungFit PH in PPHN at $350 million, worldwide sales potential for LungFit PH in PPHN at $700 million, U.S. sales potential for LungFit PRO in VCAP and bronchiolitis at $1.5 billion, worldwide sales potential for LungFit PRO in VCAP and bronchiolitis at $3 billion, U.S. sales potential for LungFit GO in NTM lung infection at $1 billion, and worldwide sales potential for LungFit GO in NTM lung infection at $2.5 billion.

Investment thesis

Bull case

Beyond Air’s first‑generation LungFit PH platform has achieved double‑digit revenue growth, doubling year‑over‑year to $2.2 million, while maintaining a 90%+ customer retention rate and securing over 45 hospital installations globally. The company’s aggressive cost discipline has trimmed operating expenses by more than a third, with SG&A and R&D reductions reflecting a leaner sales and product development structure. These financial levers translate directly into a healthier cash runway, giving management a clear pathway to sustained top‑line expansion without requiring immediate external capital beyond the recently closed $5 million equity round. The current mix of multiyear contracts and GPO agreements provides a predictable revenue base that can absorb future price increases and support margin improvement as production volumes rise.
The planned divestiture of the Neuronos subsidiary is not merely a clean‑up transaction; it represents a strategic shift that unlocks a significant milestone payment stream, potentially up to $31.5 million, while ceding a 19.9% equity stake in XTL Biopharmaceutical. This equity exposure is an added upside, as XTL’s pipeline could generate additional licensing or royalty revenue if its neuro‑oncology or autism programs succeed. The transaction therefore diversifies Beyond Air’s cash sources and reduces the company’s operational burden on the nitric oxide platform, allowing the team to focus resources on scaling Gen 2. Investors who overlook this structural realignment may miss an opportunity to capitalize on a one‑off infusion of liquidity and a long‑term equity partnership.
The U.S. Department of Veterans Affairs procurement pathway has opened a national gateway, with the first commercial sale of LungFit PH to a VA medical center. By leveraging the VA’s ECAT system, Beyond Air bypasses the typical lengthy RFP process and gains blanket access to the largest integrated health network in the country. This channel not only accelerates revenue generation but also signals institutional confidence in the product’s clinical value, which can be leveraged in future GPO negotiations and in international tender processes. The strategic advantage of VA access is a catalyst that is unlikely to be replicated by competitors without similar partnerships, thereby positioning Beyond Air ahead of peers in the nitric oxide device market.
International expansion has moved from a pipeline to reality, with distribution agreements spanning 40 countries, including Canada, Germany, Brazil, Austria, the Netherlands, and Sri Lanka. Repeat accessory orders from these partners demonstrate product stickiness and hint at a growing ecosystem of consumables, which are high‑margin revenue drivers. The diversified geographic footprint reduces concentration risk and exposes the company to emerging markets where lung disease prevalence is rising, potentially creating a new growth engine that is currently underappreciated by the market. Furthermore, the ability to serve global customers without a significant increase in fixed costs enhances scalability and supports a higher top‑line trajectory as Gen 2 gains regulatory clearance worldwide.
Management’s confidence in a Gen 2 approval before the end of 2026 is backed by consistent FDA communication and the completion of contract manufacturer inspections, which are the primary regulatory gatekeepers. Even though the company remains in the pre‑approval stage, the transparency in its regulatory strategy indicates a clear, manageable path to market entry. Once approved, Gen 2 will offer a 3,000‑hour service interval—three times longer than the first generation—thereby reducing maintenance costs for hospitals and improving operating margins. The combined effect of higher price potential and lower service frequency creates a strong value proposition that can be priced to reflect premium performance, further accelerating profitability.

Beyond Air’s first‑generation LungFit PH platform has achieved double‑digit revenue growth, doubling year‑over‑year to $2.2 million, while maintaining a 90%+ customer retention rate and securing over 45 hospital installations globally. The company’s aggressive cost discipline has trimmed operating expenses by more than a third, with SG&A and R&D reductions reflecting a leaner sales and product development structure. These financial levers translate directly into a healthier cash runway, giving management a clear pathway to sustained top‑line expansion without requiring immediate external capital beyond the recently closed $5 million equity round. The current mix of multiyear contracts and GPO agreements provides a predictable revenue base that can absorb future price increases and support margin improvement as production volumes rise.
The planned divestiture of the Neuronos subsidiary is not merely a clean‑up transaction; it represents a strategic shift that unlocks a significant milestone payment stream, potentially up to $31.5 million, while ceding a 19.9% equity stake in XTL Biopharmaceutical. This equity exposure is an added upside, as XTL’s pipeline could generate additional licensing or royalty revenue if its neuro‑oncology or autism programs succeed. The transaction therefore diversifies Beyond Air’s cash sources and reduces the company’s operational burden on the nitric oxide platform, allowing the team to focus resources on scaling Gen 2. Investors who overlook this structural realignment may miss an opportunity to capitalize on a one‑off infusion of liquidity and a long‑term equity partnership.
The U.S. Department of Veterans Affairs procurement pathway has opened a national gateway, with the first commercial sale of LungFit PH to a VA medical center. By leveraging the VA’s ECAT system, Beyond Air bypasses the typical lengthy RFP process and gains blanket access to the largest integrated health network in the country. This channel not only accelerates revenue generation but also signals institutional confidence in the product’s clinical value, which can be leveraged in future GPO negotiations and in international tender processes. The strategic advantage of VA access is a catalyst that is unlikely to be replicated by competitors without similar partnerships, thereby positioning Beyond Air ahead of peers in the nitric oxide device market.
International expansion has moved from a pipeline to reality, with distribution agreements spanning 40 countries, including Canada, Germany, Brazil, Austria, the Netherlands, and Sri Lanka. Repeat accessory orders from these partners demonstrate product stickiness and hint at a growing ecosystem of consumables, which are high‑margin revenue drivers. The diversified geographic footprint reduces concentration risk and exposes the company to emerging markets where lung disease prevalence is rising, potentially creating a new growth engine that is currently underappreciated by the market. Furthermore, the ability to serve global customers without a significant increase in fixed costs enhances scalability and supports a higher top‑line trajectory as Gen 2 gains regulatory clearance worldwide.
Management’s confidence in a Gen 2 approval before the end of 2026 is backed by consistent FDA communication and the completion of contract manufacturer inspections, which are the primary regulatory gatekeepers. Even though the company remains in the pre‑approval stage, the transparency in its regulatory strategy indicates a clear, manageable path to market entry. Once approved, Gen 2 will offer a 3,000‑hour service interval—three times longer than the first generation—thereby reducing maintenance costs for hospitals and improving operating margins. The combined effect of higher price potential and lower service frequency creates a strong value proposition that can be priced to reflect premium performance, further accelerating profitability.

Bear case

The core uncertainty surrounding the Gen 2 approval remains a substantial risk, as the product is still dependent on contract manufacturer inspections and FDA clearance. While management frames the timeline as “fairly constant,” there is no guarantee that regulatory reviews will not encounter unforeseen technical or safety objections, which could delay market entry by months or even years. Such a delay would compress the projected revenue ramp, extend the cash burn period, and potentially erode investor confidence, especially in a sector where timing is critical to capturing market share from established players.
Production scaling for Gen 2 presents a hidden operational hurdle; the company’s current COGS projections of 60–70% rely heavily on achieving economies of scale that may be difficult to realize given the device’s complex assembly and reliance on a single contract manufacturer. If the manufacturer experiences capacity constraints or cost overruns, the gross margin could suffer, and the anticipated 70% margin target may become unattainable. Such margin compression would directly impact the company’s path to profitability and could force additional capital raises, diluting existing shareholders.
Beyond Air’s product portfolio is narrowly focused on a single nitric‑oxide delivery platform. This concentration exposes the company to industry disruption from alternative oxygen therapies or new technologies that could render the device obsolete. While the company emphasizes the market potential for nitric oxide, competitors could introduce lower‑cost or higher‑efficiency alternatives, eroding market share. The company’s lack of diversification means that any technological shift or adverse regulatory developments could disproportionately impact its revenue base.
The company’s cash runway, while extended to 2027, is still relatively short in the context of medical device commercialization, where multi‑year development and market entry cycles are common. Management’s optimistic projection that cash resources will support profitability depends on hitting current revenue estimates and controlling costs, yet the company has not yet demonstrated sustained profitability at any point. Any deviation from the projected sales trajectory could force the company to seek additional financing, potentially at unfavorable terms, or to delay Gen 2 launch, thereby increasing the risk of market entry failure.
The reliance on a limited number of high‑profile customers, such as the VA and a few GPOs, introduces concentration risk; if any of these key contracts are renegotiated, reduced, or lost, the company could experience a significant revenue hit. While the company has 45 hospital installations, the market penetration is still nascent, and the majority of sales are derived from a small set of repeat buyers. A loss of even one large customer could disproportionately affect revenue and investor sentiment.

The core uncertainty surrounding the Gen 2 approval remains a substantial risk, as the product is still dependent on contract manufacturer inspections and FDA clearance. While management frames the timeline as “fairly constant,” there is no guarantee that regulatory reviews will not encounter unforeseen technical or safety objections, which could delay market entry by months or even years. Such a delay would compress the projected revenue ramp, extend the cash burn period, and potentially erode investor confidence, especially in a sector where timing is critical to capturing market share from established players.
Production scaling for Gen 2 presents a hidden operational hurdle; the company’s current COGS projections of 60–70% rely heavily on achieving economies of scale that may be difficult to realize given the device’s complex assembly and reliance on a single contract manufacturer. If the manufacturer experiences capacity constraints or cost overruns, the gross margin could suffer, and the anticipated 70% margin target may become unattainable. Such margin compression would directly impact the company’s path to profitability and could force additional capital raises, diluting existing shareholders.
Beyond Air’s product portfolio is narrowly focused on a single nitric‑oxide delivery platform. This concentration exposes the company to industry disruption from alternative oxygen therapies or new technologies that could render the device obsolete. While the company emphasizes the market potential for nitric oxide, competitors could introduce lower‑cost or higher‑efficiency alternatives, eroding market share. The company’s lack of diversification means that any technological shift or adverse regulatory developments could disproportionately impact its revenue base.
The company’s cash runway, while extended to 2027, is still relatively short in the context of medical device commercialization, where multi‑year development and market entry cycles are common. Management’s optimistic projection that cash resources will support profitability depends on hitting current revenue estimates and controlling costs, yet the company has not yet demonstrated sustained profitability at any point. Any deviation from the projected sales trajectory could force the company to seek additional financing, potentially at unfavorable terms, or to delay Gen 2 launch, thereby increasing the risk of market entry failure.
The reliance on a limited number of high‑profile customers, such as the VA and a few GPOs, introduces concentration risk; if any of these key contracts are renegotiated, reduced, or lost, the company could experience a significant revenue hit. While the company has 45 hospital installations, the market penetration is still nascent, and the majority of sales are derived from a small set of repeat buyers. A loss of even one large customer could disproportionately affect revenue and investor sentiment.

Award Type Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	177.36 Bn	27.31	4.00	12.93 Bn
2	SYK	Stryker Corp	124.60 Bn	38.40	4.96	15.86 Bn
3	MDT	Medtronic plc	109.93 Bn	23.82	3.10	28.07 Bn
4	BSX	Boston Scientific Corp	93.15 Bn	31.94	4.64	11.44 Bn
5	EW	Edwards Lifesciences Corp	46.49 Bn	43.68	7.66	0.60 Bn
6	PHG	Koninklijke Philips Nv	29.40 Bn	25.00	1.46	9.41 Bn
7	DXCM	Dexcom Inc	24.14 Bn	28.78	5.18	-
8	STE	STERIS plc	21.56 Bn	30.26	3.70	1.90 Bn

Research Tools

Beyond Air, Inc. (NASDAQ: XAIR)

About

Investment thesis

Bull case

Bear case

Award Type Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Research Tools

Beyond Air, Inc. (NASDAQ: XAIR)

About

Investment thesis

Bull case

Bear case

Award Type Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password